Form 4 for ARTV Artiva Biotherapeutics, Inc.
Accepted 2026-02-18 00:00:00 ET · period of report 2026-02-15 · accession 0001193125-26-057667 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-02-18 | 2026-02-15 | ARTV | Aslan Fred | Pres, CEO, Dir | F - Tax | $4.00 | -14.6K | 1.56M | -0.9% | -$58.4K | |
| 2026-02-18 | 2026-02-15 | ARTV | Aslan Fred | Pres, CEO, Dir | A - Grant | $0.00 | +366.9K | 1.58M | +30% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-02-15 | F | D | 14,600 | $4.00 | 1,562,198 | D | — | — | (F2) Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of restricted stock unit awards. |
| 2 | Common | Common Stock | 2026-02-15 | A | A | 366,850 | $0.00 | 1,576,798 | D | — | — | (F1) Represents restricted stock unit award granted under the Issuer's 2024 Equity Incentive Plan. |